Trial Profile
A Prospective One-arm Study of Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Locally Advanced Soft Tissue Sarcoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Doxorubicin (Primary)
- Indications Leiomyosarcoma; Myxoid liposarcoma; Neurofibrosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 24 Oct 2023 Results assessing safety and efficacy in patients with locally advanced soft tissue sarcoma (n=45) presented at the 48th European Society for Medical Oncology Congress.
- 25 Feb 2021 New trial record